Psoriasis clinical implications and treatment: A review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 3, 2013, Pages 183-216

  Raut, Ashlesha S ^a   Prabhu, Rashmi H ^a   Patravale, Vandana B ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Clinical types; Immunopathogenesis; Novel delivery systems; Psoriasis; Treatment

Indexed keywords

ADALIMUMAB; ALCLOMETASONE DIPROPIONATE; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CLOCORTOLONE PIVALATE; CYCLOSPORIN; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; FUMADERM; FUMARIC ACID; HYDROCORTISONE; HYDROXYUREA; INFLIXIMAB; KERATOLYTIC AGENT; LEFLUNOMIDE; LIAROZOLE; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; RAPAMYCIN; RETINOID; SALAZOSULFAPYRIDINE; SCYTERA; TACALCITOL; TACROLIMUS; TAR; TAZAROTENE; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABORTION; ANEMIA; ANOREXIA; ARTICLE; BEDTIME DOSAGE; BIOEQUIVALENCE; BONE MARROW SUPPRESSION; BURNING SENSATION; CHEILITIS; CHILL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; COUGHING; DEPRESSION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPEPSIA; ERYTHEMA; EXCIMER LASER; FATIGUE; FEVER; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE THERAPY; HEADACHE; HEMATOLOGIC DISEASE; HEREDITY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; KIDNEY DISEASE; LEUKOCYTOSIS; LEUKOPENIA; LIVER CIRRHOSIS; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PREVALENCE; PRURITUS; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABRASION; SKIN DISEASE; SKIN IRRITATION; STOMACH IRRITATION; T LYMPHOCYTE; TERATOGENICITY; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; UROGENITAL TRACT DISEASE;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGIC AGENTS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; PSORIASIS; RISK FACTORS; SKIN; TREATMENT OUTCOME;

EID: 84876745226     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005268     Document Type: Article

References (184)

1. Tzu J, Mamelak AJ, Sauder DN. Current advancements in the treatment of psoriasis: Immunobiologic agents. Clin Appl Immunol Rev. 2006;6:99-130.
2. Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986;14(5 Pt 1):863-6.
3. Shai A, Vardy D, Zvulunov A. Psoriasis, biblical afflictions and patients' dignity. Harefuah. 2002;141(5):479-82,496.
4. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4): 314-20.
5. Jullien D. Psoriasis physiopathology. J Eur Acad Dermatol Venereol. 2006;20 Suppl 2:S10-23.
6. Galadari I, Sharif MO, Galadari H. Psoriasis: a fresh look. Clin Dermatol. 2005;23(5):491-502.
7. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev. 2007;6(8):515-9.
8. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol. 2010;76(6):612-21.
9. Robbins PD, Evans CH. Prospects for treating autoimmune and inflammatory diseases by gene therapy. Gene Ther. 1996;3(3):187-9.
10. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24(1):52-57.
11. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl): S57-61.
12. De Arruda LH, De Moraes AP. Impact of psoriasis on quality of life. Br J Dermatol. 2001;144 Suppl 58:S33-6.
13. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-9.
14. Jullien D, Barker JN. Genetics of psoriasis. J Eur Acad Dermatol Venereol. 2006;20 Suppl 2: S42-51.
15. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23-6.
16. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2:ii18-ii23.
17. Henseler T. The genetics of psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S1-S11.
18. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-204.
19. Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, Ozawa A, Ohkawara A, Kobayashi H, Harada S, Igarashi A. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31(1):59-64.
20. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol. 2003;49(2 Suppl):S51-6.
21. Sagoo GS, Cork MJ, Patel R, Tazi-Ahnini R. Genome-wide studies of psoriasis susceptibility loci: a review. J Dermatol Sci. 2004;35(3):171-9.
22. Stern RS. Psoriasis. Lancet. 1997;350(9074):349-53.
23. Stevenson O, Zaki I. Introduction to psoriasis. Hospital Pharmacist. 2002;9:187-90.
24. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol. 2004;50(4):613-22.
25. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005;38(3):235-45.
26. Krishna K. Koebner response in psoriasis. Indian J Dermatol Venereol Leprol. 1998; 64(1):42-3.
27. Basavaraj S, Wardrop P, Sivaji N, Shanks M, Allen AA. Cochlear implantation in psoriasis patients. Auris Nasus Larynx. 2007;34(2):221-3.
28. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007;21(7):901-12.
29. Mamkin I, Mamkin A, Ramanan SV. HIV-associated psoriasis. Lancet Infect Dis. 2007;7(7): 496.
30. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. 2005;52(1): 1-19.
31. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol. 2000;25(2):107-10.
32. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768-73.
33. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56(6):901-16.
34. Bren L. Psoriasis: more than cosmetic. FDA Consum. 2004;38(5):10-6.
35. Sticherling M. Mechanisms of psoriasis. Drug Discov Today Dis Mech. 2005;2(2):275-81.
36. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20(1):40-6.
37. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S67-80.
38. Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. J Autoimmun. 2005;25 Suppl:69-73.
39. Sobell JM. Overview of biologic agents in medicine and dermatology. Semin Cutan Med Surg. 2005;24(1)24:2-9.
40. Portugal M, Barak V, Ginsburg I, Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: present status and future considerations. Biomed Pharmacother. 2007;61(7): 412-422.
41. Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem. 2006;39(2):119-25.
42. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol. 2002;23(1):47-53.
43. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine.2006;33(2):72-8.
44. Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17 Suppl 2:S1-5.
45. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438-47.
46. Goupille P. Psoriatic arthritis. Joint Bone Spine. 2005;72(6):466-70.
47. Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol. 2000;42(5 Pt 2):885-7.
48. Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 1996;34(5 Pt 2):911-4.
49. Ozkaya-Bayazit E, Akasya E, Büyükbabani N, Baykal C. Pustular psoriasis with a striking linear pattern. J Am Acad Dermatol. 2000;42(2 Pt 2):329-31.
50. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.
51. Young Park J, Hyun Rim J, Beom Choe Y, II Youn J. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004;50(4):582-4.
52. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S59-69.
53. Berth-Jones J. Psoriasis. Medicine. 2005;33(1):50-5.
54. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53(1):101-7.
55. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000;25(1):1-10.
56. Lebwohl M, Ali S. Treatment of Psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649-61.
57. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Current systemic therapies for psoriasis: Where are we now? J Am Acad Dermatol. 2003;49(2 Suppl):S66-77.
58. Koo J. Neoral in psoriasis therapy: towards a new perspective. Int J Dermatol. 1997;36 Suppl 1:25-9.
59. Georgouras KE, Zagarella SS, Cains GD, Brown PJ. Systemic treatment of severe psoriasis. Australas J Dermatol. 1997;38(4):171-82.
60. Hernanz JM, Puig L, Daudén E. Safety of cyclosporine in patients with psoriasis. J Am Acad Dermatol. 2004;50(3 Suppl):S145.
61. Adler-Moore JP, Chiang S, inventors; NeXstar Pharmaceuticals, Inc, assignee. Liposomal cyclosporin pharmaceutical formulation. United States Patent US5683714A. 1997 Nov 4.
62. Marriott C, Martin GP, Brown MB, inventors; Jagotec AG, assignee. Hyaluronic drug delivery system. United States Patent US6890901B2 2005 May 10.
63. Egbaria KF, Groves MJ, inventors. Spontaneous emulsions containing cyclosporine. United States Patent US6960563B2. 2005 Nov 1.
64. Floch R, Merle C, inventors; Sangstat Medical Corporation, assignee. Cyclosporin A formulations as nanoparticles. United States patent US5827822A 1998 Oct 27.
65. Avramoff A, Khan W, Ezra A, Elgart A, Hoffman A, Domb AJ. Cyclosporin pro-dispersion liposphere formulation. J Control Release. 2012;160(2):401-6.
66. Avramoff A, Laor A, Kitzes-Cohen R, Farin D, Domb AJ. Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations. Int J Clin Pharmacol Ther. 2007;45(2):126-32.
67. Murdan S, Andrýsek T, Son D. Novel gels and their dispersions-oral drug delivery systems for ciclosporin. Int J Pharm. 2005;300(1-2):113-24.
68. Andrysek T. Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Mol Immunol. 2003;39(17-18):1061-5.
69. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporine A in solid lipid nanoparticles (SLN). Int J Pharm. 2002;241(2):341-4.
70. Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm. 2001;216(1-2):17-21.
71. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13-23.
72. Dubertret L. Methotrexate in dermatology and rheumatology. Joint Bone Spine. 2005;72(2): 104-5.
73. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38(3):478-85.
74. Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. 2000;42(5 Pt 1):835-7.
75. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997;37(3 Pt 1):445-9.
76. Gottlieb A. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S3-16.
77. Mendonça CO, Burden AD. Current concepts in psoriasis and its treatment. Pharmacol Ther. 2003;99(2):133-47.
78. Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol. 2005;153(3):549-51.
79. Kaltwasser JP. Leflunomide in psoriatic arthritis. Autoimmun Rev.2007;6(8):511-4.
80. Mason C, Krueger GG. Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol. 2001;44(1):67-72.
81. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-85.
82. Lebwohl M, Ali S. Treatment of psoriasis: Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45(4):487-98.
83. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S17-25.
84. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000 Feb;25(1):1-10.
85. Clark AR. Topical noncorticosteroid therapies for psoriasis. Curr Probl Dermatol. 2000;12(5):230-2.
86. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1): 16-24.
87. Rao S, Dixit S, Obe F, Yacobi A, inventors. Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same. United States Patent 20060246098A1.2006 Nov 2.
88. Wargon O, Paver WK. Dithranol in a cream base in the treatment of psoriasis. Australas J Dermatol. 1982;23(3):123-5.
89. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-washoil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol. 2004;17(2):91-7.
90. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228(1-2):43-52.
91. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol. 2002;29(8):529-32.
92. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat. 2007;18(1):40-5.
93. Gidwani SK, Singnurkar PS. Inventors. Composition for delivery of dithranol. United States Patent 20030219465A1.2003 Nov 27.
94. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous asorption studies. J Microencapsul. 2011;28(3):190-9.
95. Guenther U, Smirnova I, Neubert RH. Hydrophilic silica aerogels as dermal drug delivery systemsdithranol as a model drug. Eur J Pharm Biopharm. 2008;69(3):935-42.
96. Houston E, inventor. Psoriasis formulation and method of preparation. United States Patent 20050098502A1. 2005 May 12.
97. Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol. 2010;3(9):37-40.
98. Bhatia A, Singh B, Amarji B, Negi P, Shukla A, Katare OP. Novel stain-free lecithinized coal tar formulation for psoriasis. Int J Dermatol. 2011;50(10):1246-8.
99. Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol. 2009;8(4):282-8.
100. Kovalovsky D, Refojo D, Holsboer F, Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol. 2000;109(1 Suppl 1):S23-9.
101. Payne DNR, Adcock I. Molecular mechanisms of corticosteroid actions. Paediatr Respir Rev. 2001;2(2):145-50.
102. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S50-8.
103. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15.
104. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628-32.
105. Huang X, Tanojo H, Lenn J, Deng CH, Krochmal L. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol. 2005;53(1 Suppl 1):S26-38.
106. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397-406.
107. Sanchez Regana M, Martin Ezquerra G, Umbert Millet P, Llambi Mateos F. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol. 2005;19(5):573-7.
108. Badilli U, Sen T, Tarimci N. Microparticulate based topical delivery system of clobetasol propionate. AAPS PharmSciTech. 2011;12(3):949-957.
109. Zhang J, Smith E. Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J Pharm Sci. 2011;100(3):896-903.
110. Senyigit T, Sonvico F, Barbieri S, Ozer O, Santi P, Colombo P. Lecithin/chitosan nanoparticles of clobetasol- 17-propionate capable of accumulation in pig skin. J Control Release. 2010;142(3):368-73.
111. Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem. 2006;14(13):4323-40.
112. Marks R. The role of tazarotene in the treatment of psoriasis. Br J Dermatol. 1999;140 Suppl 54:24-8.
113. Nishii Y, Okano T. History of the development of new vitamin D analogs: studies on 22- oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy)calcitriol (ED-71). Steroids. 2001;66(3-5):137-46.
114. Bouillon R, Verlinden L, Eelen G, De Clercq P, Vandewalle M, Mathieu C, Verstuyf A. Mechanisms for the selective action of Vitamin D analogs. J Steroid Biochem Mol Biol. 2005;97(1-2):21-30.
115. Lecha M, Mirada A, López S, Artés M. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience. J Eur Acad Dermatol Venereol. 2005;19(4):414-7.
116. Naeff R, Delmenico S, Spycher R, Corbo M, Flother F, inventors, Cliag AG, assignee. Liposomebased topical vitamin D formulation. United States Patent US5834016A. 1998 Nov 10.
117. Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine. 2010;5:117-28.
118. Prufer K, Jirikowski GF. Liposomal incorporation changes the effect of 1.25-dihydroxyvitamin D3 on the phospholipase C signal transduction pathway and the eicosanoid cascade on keratinocytes in vitro. Biochem Pharmacol. 1996;51(3):247-52.
119. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134(6):1070-8.
120. Ling MR. Topical tacrolimus and pimecrolimus: future directions. Semin Cutan Med Surg. 2001;20(4):268-74.
121. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002;27(7):555-61.
122. Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm. 2011;79(1):82-94.
123. Erdogan M, Wright JR, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol. 2002;146(6):964-7.
124. Li G, Fan C, Li X, Fan Y, Wang X, Li M, Liu Y. Preparation and in vitro evaluation of tacrolimusloaded ethosomes. ScientificWorldJournal. 2012;2012:874053.
125. Goebel AS, Neubert RH, Wohlrab J. Dermal targeting of tacrolimus using colloidal carrier systems. Int J Pharm. 2011;404(1-2):159-68.
126. Gajardo J, Villaseca J. Psoriasis and cyclosporine: an attempt at topical treatment. Rev Med Chil. 1994;122(12):1404-7.
127. Tran HS, Malli D, Chrzanowski FA, Puc MM, Matthews MS, Hewitt CW. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. J Surg Res. 1999;83(2):136-40.
128. Duncan JI, Wakeel RA, Winfield AJ, Ormerod AD, Thomson AW. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Derm Venereol. 1993;73(2):84-7.
129. Liu H, Li S, Wang Y, Yao H, Zhang Y. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharm. 2006;311(1-2):182-6.
130. Lopes LB, Collett JH, Bentley MV. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur J Pharm Biopharm. 2005;60(1):25-30.
131. Lopes LB, Lopes JL, Oliveira DC, Thomazini JA, Garcia MT, Fantini MC, Collett JH, Bentley MV. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm. 2006;63(2):146-55.
132. Katare OP, Kumar R, Bhoop BS, Dogra S, Kaur I. A multicompartmental liposomal system for topical drug delivery. Kolkata(India): The Patent office Journal. 2009:6210.
133. Katare OP, Kumar R, Bhoop BS, Dogra S, Kaur I. Microemulsion organogel system for site-specific delivery of cyclosporine. Kolkata(India): The Patent office Journal. 2009:6211.
134. Guo J, Ping Q, Sun G, Jiao C. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm. 2000;194(2):201-7.
135. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. Iontophoresis of lecithin vesicles of cyclosporine A. Int J Pharm. 2004;274:185-90.
136. Liu H, Li S, Pan W, Wang Y, Han F, Yao H. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. Int J Pharm. 2006;326(1-2):32-8.
137. Sutton L, Swinehart JM, Cato A, Kaplan AS. A clinical study to determine the efficacy and safety of 1% Methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol. 2000;40(7):464-7.
138. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv. 1996;71(2):135-40.
139. Moghimi SM, Patel HM. Current progress and future prospects of liposomes in dermal drug delivery. J Microencapsul. 1993 Apr-Jun;10(2):155-62.
140. Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm. 2012;427(2):426-34.Epub 2012 Jan 30.
141. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;270(1-2):119-25.
142. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol. 2007;73(3):157-61.
143. Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 2008;14(12):I66-74.
144. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 2007;123(2):148-54.
145. Misra AK, Padhi BK, Chugule M. Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation and clinical clinical implications. Drug Del Tech. 2004;4:8.
146. Jahn K, Fischer A, Neubert RH, Wohlrab J. Investigation of the penetration behaviour of mycophenolate mofetil from a semisolid formulation into human skin ex-vivo. J Pharm Pharmacol. 2001;53(12):1581-7.
147. Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401(1-2):93-102.
148. Neill WA, Halliday KE, Norval M. Differential effect of phototherapy on the activities of human natural killer cells and cytotoxic T cells. J Photochem Photobiol B. 1998;47(2-3):129-35.
149. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol. 2004;195(3):298-308.
150. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003;49(2 Suppl):S78-86.
151. McEvoy MT, Stern RS. Psoralens and related compounds in the treatment of psoriasis. Pharmacol Ther. 1987;34(1):75-97.
152. Laskin JD, Lee E. Psoralen binding and inhibition of epidermal growth factor binding by psoralen/ ultraviolet light (PUVA) in human epithelial cells. Biochem Pharmacol. 1991;41(1):125-32.
153. Herr H, Cho HJ, Yu S. Burns caused by accidental overdose of photochemotherapy (PUVA). Burns. 2007;33(3):372-5.
154. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001;44(5):755-61.
155. Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000;69(1):209-218.
156. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633-40.
157. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol. 2006;24(1):33-42.
158. Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors. J Am Acad Dermatol. 2003;49(2 Suppl):S39-43.
159. Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, García- Bustinduy M, Bordas X, Moreno JC, Hernanz JM, Laguarda S, García-Patos V. Spanish evidencebased guidelines on the treatment of moderate to severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009;100(5):386-413.
160. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49(2 Suppl):S44-50.
161. Dogra A, Sachdeva S. Biologic therapy in psoriasis. Indian J Dermatol Venereol Leprol. 2006;72(4):256-64.
162. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol. 2007;123(2): 129-38.
163. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci. 2005;38(2):75-87.
164. Kipnis CD, Myers WA, Opeola M, Gottlieb AB. Biologic treatments for psoriasis. J Am Acad Dermatol 2005;52(4):671-82.
165. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005;53(2):346-51.
166. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6-14.
167. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther. 2003;25(10):2487-505.
168. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416-430.
169. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg. 2005;24(1):37-45.
170. News release: FDA approves Taclonex® once daily therapy for treatment of Psoriasis- [cited 2006 Jan 10]. Available from: http://www.wcrx.com/pdfs/1_10_06_fda_approv_taclonex.pdf
171. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlöndorff D, Plewig G, Sander CA, Röcken M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9(1):40-6.
172. Li J, Li X, Zhang Y, Zhou XK, Yang HS, Chen XC, Wang YS, Wei YQ, Chen LJ, Hu HZ, Liu CY. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med. 2010;12(6):481-90.
173. Zhang Y, Li J, Liu CY, Zhou XK, Qiu J, Zhang YB, Huang NY, Li Y, Chen XJ, Li XL, Wang YS, Yang HS, Chen XC, Kan B, Mao YQ, Deng HX, Yang L, Wen YJ, Zhao X, Wei YQ. A novel transdermal plasmid-dimethylsulfoxide delivery technique for treatment of psoriasis. Dermatology. 2010;221(1):84-92.
174. Chang T, Sun L, Wang Y, Wang D, Li W, Li C, Gao T, Liu Y, Wang G. Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis. Exp Dermatol. 2011;20(7):555-60.
175. Zibert JR, Wallbrecht K, Schön M, Mir LM, Jacobsen GK, Trochon-Joseph V, Bouquet C, Villadsen LS, Cadossi R, Skov L, Schön MP. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. J Clin Invest.2011;121(1):410-21.
176. Tincani A, Andreoli L, Bazzani C, Bosiso D, Sozzani S. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev. 2007;7(1):1-7.
177. Cather JC, Cather JC, Abramovits W. Investigational therapies for psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl):S133-8.
178. Shimizu K, Kawase A, Haneishi T, Kato Y, Kobayashi T, Sekiguchi N, Yamamoto T, Ishigai M, Tokuda K, Matsushita T, Shimaoka S, Morikawa K. Novel vitamin D3 antipsoriatic antedrugs: 16-En- 22-oxa-1alpha,25-(OH)2D3 analogs. Bioorg Med Chem. 2006;14(6):1838-50.
179. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005;19(1):1-20.
180. Fry L, Baker BS, Powles AV. Psoriasis-a possible candidate for vaccination. Autoimmun Rev. 2007;6(5):286-9.
181. Kushelevsky AP, Harari M, Hristakieva E, Shani J. Climatotherapy of psoriasis and hypertension in elderly patients at the Dead Sea. Pharmacol Res. 1996;34(1-2):87-91.
182. Sayilia M, Akca H, Dumanb T, Esengun K. Psoriasis treatment via doctor fishes as part of health tourism: A case study of Kangal Fish Spring, Turkey. Tourism Management. 2007;28(2):625-9.
183. Mikula C. Balneo-phototherapy: a new holistic approach to treating psoriasis. J Am Acad Nurse Pract. 2003;15(6):253-9.
184. Graham GF, Barham KL. Cryosurgery. Curr Probl Dermatol. 2003;15(6): 229-50.